ACLURITY

Glaxo Group Limited

Application Filed: 2012-11-09

Trademark Application Details

Status

606

Dead/Abandoned

ABANDONED - NO STATEMENT OF USE FILED

Research	OneLook Acronym Finder
Serial Number	85775738
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Attorney Name	Christopher M. Hanes
Attorney Docket Number	TMR\5088184\
Law Office Assigned	M70
Employee Name	BRACEY, KAREN E

Timeline

2012-11-09	Application Filed
2013-05-07	Published for Opposition
2014-07-15	Location: INTENT TO USE SECTION
2015-02-02	Abandon
2015-02-02	Status: Dead/Abandoned
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	Glaxo Group Limited
Address	980 Great West Road Brentford, Middles GB TW89GS
Legal Entity Type	Corporation
Legal Entity State	GB

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

CHRISTOPHER M. HANES
GLAXOSMITHKLINE
5 MOORE DR
RESEARCH TRIANGLE PARK, NC 27709-0183

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(e)) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Type Code

Type

GS0051

(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(e)) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2012-11-13	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2012-11-16	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2013-03-04	3 DOCK D:Assigned to Examiner
APPROVED FOR PUB - PRINCIPAL REGISTER	2013-03-06	4 CNSA P:
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED	2013-03-15	5 ERRR O:Outgoing Correspondence
TEAS CHANGE OF OWNER ADDRESS RECEIVED	2013-03-20	6 COAR I:Incoming Correspondence
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED	2013-03-20	7 CHAN I:Incoming Correspondence
ELECTRONIC RECORD REVIEW COMPLETE	2013-04-01	8 FIXD O:Outgoing Correspondence
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	2013-04-17	9 NONP E:E-Mail
PUBLISHED FOR OPPOSITION	2013-05-07	10 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2013-05-07	11 NPUB E:E-Mail
NOA E-MAILED - SOU REQUIRED FROM APPLICANT	2013-07-02	12 NOAM E:E-Mail
TEAS EXTENSION RECEIVED	2013-12-16	13 EEXT I:Incoming Correspondence
EXTENSION 1 FILED	2013-12-16	14 EXT1 S:
EXTENSION 1 GRANTED	2013-12-16	15 EX1G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2013-12-18	16 EXRA E:E-Mail
TEAS EXTENSION RECEIVED	2014-06-23	17 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL	2014-07-15	18 AITU A:Allowance for Publication
EXTENSION 2 FILED	2014-06-23	19 EXT2 S:
EXTENSION 2 GRANTED	2014-07-16	20 EX2G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2014-07-17	21 EXRA E:E-Mail
ABANDONMENT - NO USE STATEMENT FILED	2015-02-02	22 ABN6 S:
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED	2015-02-02	23 MAB6 O:Outgoing Correspondence

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.